Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
1. Subjects with histologically or cytologically confirmed advanced / metastatic or surgically unresectable solid tumors whose tumors are refractory to standard therapy.
2. Measurable disease per RECIST v 1.1 (primary or metastatic disease).
3. ECOG performance status 0 - 1.
4. Life expectancy of at least 3 months.
5. Age ≥ 18 years.
6. Signed, written Institutional Review Board (IRB) approved informed consent
7. A negative serum pregnancy test (for nonsterile women of child-bearing potential).
8. Acceptable liver function:
- Bilirubin ≤ 1.5 times upper limit of normal;
- AST (SGOT), ALT (SGPT) ≤ 5 times upper limit of normal because of cancer or metastases to the liver.
9. Acceptable renal function, defined as:
o Serum creatinine ≤ 1.5 ULN or Creatinine Clearance ≥ 50 mL/minute.
10. Acceptable hematologic status:
- Hemoglobin ≥ 9 g/dL (a transfusion is allowed if Hemoglobin stays stable thereafter);
- Absolute neutrophil count (ANC) ≥ 1,000 cells/mm^3;
- Platelet count ≥ 100,000 plt/mm^3 x 10^9/ L.
11. Urinalysis with no clinically significant abnormalities.
12. Acceptable coagulation status with partial thromboplastin time (PTT) and International Normalized Ratio (INR) ≤ 1.5 times upper limit of normal unless patient is on anti-coagulants and has stable PTT and PT that are within normal therapeutic range for disease under management.
13. Subject has adequate vitamin D level, as defined by serum total 25-Hydroxyvitamin D [25(OH)D] ≥ 20 to < 60 ng/mL. If subjects are below this threshold, they may receive
vitamin D supplementation se per clinic dosing guidelines and may still be enrolled provided they are started on vitamin D supplementation.
14. Completion of all previous treatments (including surgery, systemic chemotherapy, and radiotherapy) at least 3 weeks before screening.
15. For men and women of child-producing potential, the use of effective contraceptive methods during the study.
1. Baseline Q-T corrected interval (QTc) interval of > 470 msec for all subjects calculated using Fridericia's formula.
2. New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/ peripheral artery bypass graft, congestive heart failure within the past 6 months.
3. Known active, uncontrolled infection with HIV or hepatitis B; subjects with hepatitis B allowed if on anti-viral therapy and have a viral load ≤ 500 IU; patients with a history of HIV must be on antiretroviral therapy for at least four weeks and have an HIV viral load ≤ 400 copies/mL, have CD4+ T cell counts ≥ 350 cells/uL and no history of AIDS-defining opportunistic infections within 3 months prior to treatment.
4. Major surgical procedure within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure, during the course of the study.
Note: Placement of a central venous access catheter(s) (e.g., port or similar) is not
considered a major surgical procedure.
5. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
6. Pregnant or nursing women.
Note: Women of child-bearing potential and men must agree- to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
7. Participation in a clinical study involving administration of an investigational compound within the past 30 days prior to study entry.
8. Unwillingness or inability to comply with procedures required in this protocol.
9. Known allergy or hypersensitivity to the study drug(s) or one of the ingredients in the formulation (e.g., Trehalose dihydrate).
10. Existence of any surgical, medical or laboratory condition that, in the judgment of the clinical investigator, might interfere with the safety, distribution, metabolism
or excretion of the drug.
Eligibility last updated 4/11/22. Questions regarding updates should be directed to the study team contact.